Send to

Choose Destination
Cancer Discov. 2019 Aug 30. doi: 10.1158/2159-8290.CD-NB2019-103. [Epub ahead of print]

Targeting WEE1 in Pancreatic Cancer.

[No authors listed]


According to results from a phase I/II trial, the investigational WEE1 inhibitor adavosertib combined with gemcitabine and radiation is well tolerated and may benefit patients with locally advanced pancreatic adenocarcinoma by increasing both systemic and local disease control.

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center